Medication info
Positam Extended Release Tablets 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

Positam Extended Release Tablets 5/50/1000 mg (Dapagliflozin, Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tabletDapagliflozin Propanediol Hydrate›6.15mg / 1 tablet
Manufacturer / importer
Genewon Science Co., Ltd.
Appearance
Orange oval extended release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202401773 · Approved 2024.07.23 · Insurance code 671707430

Summary

Main use
Improvement of blood glucose control in type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this medicine for antidiabetic therapy is 10 mg of dapagliflozin and 100 mg of sitagliptin; the dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is required in patients with mild renal impairment. If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other symptoms that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.

Ingredients

Manufacturer
Genewon Science Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in type 2 diabetes

View approved original text

This medication is used for patients with type 2 diabetes to improve blood sugar control while assisting meal therapy and exercise therapy when taken with dapagliflozin, sitagliptin, and metformin.

How to take

Adult dose

The recommended dose of this medicine for antidiabetic therapy is 10 mg of dapagliflozin and 100 mg of sitagliptin; the dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the existing dose of each component. No dose adjustment is required in patients with mild renal impairment. If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other symptoms that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.

Precautions

This medication contains three components: sitagliptin, dapagliflozin, and metformin. First, the sitagliptin component can cause severe allergic reactions, so if you experience skin rash, difficulty breathing, or swelling of the face or lips, you must stop taking this medication immediately. Additionally, acute pancreatitis may occur, which means inflammation of the pancreas, so if sudden abdominal pain or vomiting occurs, you should visit the hospital quickly. Next, the metformin component can rarely cause a serious metabolic disorder called lactic acidosis. This symptom occurs due to the accumulation of lactic acid in the body, and symptoms such as weakness, muscle pain, difficulty breathing, and abdominal pain may appear, so if these symptoms occur, you should consult a healthcare professional immediately. Moreover, it is safer not to use this medication for patients with decreased kidney function, severe infections, dehydration, heart failure, or unstable conditions such as acute myocardial infarction. Patients who are scheduled to receive iodine contrast agents for radiological examinations should discontinue this medication for a certain period before and after the examination and should resume taking it only after confirming normal kidney function. Patients with decreased blood volume or low blood pressure, the elderly, or patients taking diuretics should carefully monitor their condition as they may be at risk for decreased blood pressure or worsening kidney function while using this medication. Infections of the genital area and urinary tract may occur during the use of this medication, so if related symptoms appear, immediate treatment should be sought. Additionally, hypoglycemic symptoms may occur, so especially when combined with other diabetes medications such as insulin or sulfonylureas, blood sugar changes should be monitored closely. It is advisable not to use this medication during pregnancy, when there are issues with placental function, or in patients with significantly reduced liver function. Finally, this medication can rarely cause skin rash, urticaria, severe joint pain, and blistering skin diseases, so if abnormal symptoms occur, you should consult a doctor immediately. During the use of this medication, it is essential to regularly check health status through blood tests and kidney function tests.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia
Show 142 more
  • genital infection
  • vulvitis
  • balanitis
  • fungal infection
  • perineal necrosis
  • fluid volume reduction
  • dehydration
  • hypovolemia
  • hypotension
  • diabetic ketoacidosis
  • urinary tract infection
  • cystitis
  • E. coli urinary tract infection
  • genitourinary infections
  • pyelonephritis
  • trigonal cystitis
  • urethritis
  • kidney infection
  • prostatitis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • interstitial nephritis
  • vulvar pruritus
  • genital pruritus
  • increased hematocrit
  • decreased serum creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • rash
  • generalized rash
  • pruritic rash
  • maculopapular rash
  • papular rash
  • pustular rash
  • vesicular rash
  • erythematous rash
  • acute renal failure
  • upper respiratory tract infection
  • nasopharyngitis
  • constipation
  • vomiting
  • headache
  • severe arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • gastroesophageal reflux disease
  • epigastric pain
  • diverticulosis
  • intestinal perforation
  • chronic pancreatitis
  • hyperglycemia
  • paresthesia
  • cerebral infarction
  • nerve compression
  • sinusitis
  • diverticulitis
  • pelvic inflammatory disease
  • pneumonia
  • pulmonary tuberculosis
  • asthenia
  • pain
  • ligament sprain
  • road traffic accident
  • drug overdose
  • ankle fracture
  • hand fracture
  • iliac fracture
  • meniscus injury
  • thoracic vertebra fracture
  • tibial fracture
  • keratitis
  • chronic obstructive pulmonary disease
  • hemoptysis
  • cerebral hemorrhage
  • peripheral artery occlusion
  • angina
  • myocardial infarction
  • bile duct stones
  • cholangitis
  • alcoholic liver cirrhosis
  • depression
  • suicide attempt
  • gastric adenocarcinoma
  • anaphylactic reaction
  • acute pyelonephritis
  • chest pain
  • dyspepsia
  • nausea
  • diarrhea
  • vomiting
  • urinary retention
  • elevated alanine aminotransferase
  • elevated aspartate aminotransferase
  • decreased appetite
  • next-day syndrome
  • headache
  • nasopharyngitis
  • asthenia
  • hunger
  • vaginal discharge
  • pruritus
  • urticaria
  • sweating
  • arthralgia
  • musculoskeletal pain
  • limb pain
  • muscle weakness
  • myalgia
  • osteoarthritis
  • ligament sprain
  • diabetic retinopathy
  • cough
  • dyspnea
  • orthostatic hypotension
  • palpitations
  • insomnia
  • fatty liver
  • gallbladder polyp
  • tinnitus
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • appetite loss
  • erythema
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and light, at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the medication's effectiveness over time.

Appearance and packaging

Appearance

Orange oval extended release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.